212 related articles for article (PubMed ID: 24222719)
21. Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study.
Ajeganova S; Fiskesund R; de Faire U; Hafström I; Frostegård J
Clin Exp Rheumatol; 2011; 29(6):942-50. PubMed ID: 22153361
[TBL] [Abstract][Full Text] [Related]
22. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
[TBL] [Abstract][Full Text] [Related]
23. Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis.
Sandoo A; Dimitroulas T; Toms TE; Hodson J; Veldhuijzen van Zanten JJ; Smith JP; Kitas GD
Clin Biochem; 2012 Nov; 45(16-17):1399-403. PubMed ID: 22820438
[TBL] [Abstract][Full Text] [Related]
24. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
25. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
Ikeda K; Nakagomi D; Sanayama Y; Yamagata M; Okubo A; Iwamoto T; Kawashima H; Takahashi K; Nakajima H
J Rheumatol; 2013 Dec; 40(12):1967-76. PubMed ID: 24187096
[TBL] [Abstract][Full Text] [Related]
26. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
27. Low circulating level of CD133+KDR+cells in patients with systemic sclerosis.
Mok MY; Yiu KH; Wong CY; Qiuwaxi J; Lai WH; Wong WS; Tse HF; Lau CS
Clin Exp Rheumatol; 2010; 28(5 Suppl 62):S19-25. PubMed ID: 21050541
[TBL] [Abstract][Full Text] [Related]
28. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G
Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315
[TBL] [Abstract][Full Text] [Related]
29. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.
Li S; Kaur PP; Chan V; Berney S
Clin Rheumatol; 2009 Jul; 28(7):787-91. PubMed ID: 19291350
[TBL] [Abstract][Full Text] [Related]
30. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
[TBL] [Abstract][Full Text] [Related]
31. Ultrasound Doppler measurements predict success of treatment with anti-TNF-α drug in patients with rheumatoid arthritis: a prospective cohort study.
Ellegaard K; Christensen R; Torp-Pedersen S; Terslev L; Holm CC; Kønig MJ; Jensen PS; Danneskiold-Samsøe B; Bliddal H
Rheumatology (Oxford); 2011 Mar; 50(3):506-12. PubMed ID: 21071479
[TBL] [Abstract][Full Text] [Related]
32. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.
Hayashi M; Kojima T; Funahashi K; Kato D; Matsubara H; Shioura T; Kanayama Y; Hirano Y; Ishiguro N
Mod Rheumatol; 2012 Jun; 22(3):363-9. PubMed ID: 21979824
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).
Virkki LM; Valleala H; Takakubo Y; Vuotila J; Relas H; Komulainen R; Koivuniemi R; Yli-Kerttula U; Mali M; Sihvonen S; Krogerus ML; Jukka E; Nyrhinen S; Konttinen YT; Nordström DC
Clin Rheumatol; 2011 Nov; 30(11):1447-54. PubMed ID: 21644062
[TBL] [Abstract][Full Text] [Related]
34. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis.
Tikiz H; Arslan O; Pirildar T; Tikiz C; Bayindir P
Anadolu Kardiyol Derg; 2010 Apr; 10(2):98-103. PubMed ID: 20382605
[TBL] [Abstract][Full Text] [Related]
35. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
[TBL] [Abstract][Full Text] [Related]
36. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension.
Diller GP; van Eijl S; Okonko DO; Howard LS; Ali O; Thum T; Wort SJ; Bédard E; Gibbs JS; Bauersachs J; Hobbs AJ; Wilkins MR; Gatzoulis MA; Wharton J
Circulation; 2008 Jun; 117(23):3020-30. PubMed ID: 18519847
[TBL] [Abstract][Full Text] [Related]
37. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.
Naredo E; Möller I; Cruz A; Carmona L; Garrido J
Arthritis Rheum; 2008 Aug; 58(8):2248-56. PubMed ID: 18668537
[TBL] [Abstract][Full Text] [Related]
38. Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer.
Su Y; Zheng L; Wang Q; Li W; Cai Z; Xiong S; Bao J
J Exp Clin Cancer Res; 2010 Mar; 29(1):27. PubMed ID: 20334653
[TBL] [Abstract][Full Text] [Related]
39. Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation.
Herenius MM; Oliveira AS; Wijbrandts CA; Gerlag DM; Tak PP; Lebre MC
PLoS One; 2013; 8(2):e57802. PubMed ID: 23460910
[TBL] [Abstract][Full Text] [Related]
40. Effects of TNF inhibitor on innate inflammatory and Th17 cytokines in stimulated whole blood from rheumatoid arthritis patients.
Zivojinovic S; Pejnovic N; Sefik-Bukilica M; Kovacevic L; Soldatovic I; Bugarski D; Mojsilovic S; Damjanov N
Inflammopharmacology; 2012 Dec; 20(6):323-30. PubMed ID: 22733231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
